# A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

> **NCT06006598** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1584862
- **DRUG:** Placebo matching BI 1584862
- **DRUG:** midazolam

## Key facts

- **NCT ID:** NCT06006598
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-28
- **Primary completion:** 2024-05-05
- **Final completion:** 2024-05-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006598, "A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06006598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*